Patent · US Active

Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator

US10208073B2 · kind B2 · utility

0Cited by

12References

13Claims

0Family size

Assignee

Helsinn Healthcare SA · CH

Inventors

Luca Fadini · Giubiasco, CH
Peter Manini · Giubiasco, CH
Claudio Pietra · Como, IT
Claudio Giuliano · Como, IT
Emanuela Lovati · Mendrisio, CH
Roberta Cannella · Varese, IT
Alessio Venturini · Varese, IT
Valentino J. Stella · Lawrence, US

Key dates

Filing date	Jan 18, 2018
Grant date	Feb 19, 2019
Priority date	—
Expiry date	Jan 18, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07F9/650952
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone and its application in methods for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.